Jazz Pharmaceuticals (JAZZ) Stock Looks Overvalued With A 90% Three Year Run

Nov 21, 2026
jazz-pharmaceuticals-(jazz)-stock-looks-overvalued-with-a-90%-three-year-run

Bailey Pemberton

4 min read

Jazz Pharmaceuticals has delivered a strong share price story over the past few years, and that kind of run always raises the same question for investors who care about valuation. Is the current price still anchored in what the business is earning, or has the Jazz Pharmaceuticals stock chart moved faster than its underlying profits?

  • Over the past 3 years the share price has returned 89.7%, which puts real weight on whether the current valuation can be explained by earnings power rather than momentum alone.

  • Recent trial outcomes around Zepzelca and other oncology programs may influence how investors think about future earnings resilience, cash generation and what multiple they are prepared to pay for Jazz Pharmaceuticals today.

  • There is a second opinion on Jazz Pharmaceuticals worth weighing. See what analysts think Jazz Pharmaceuticals’s shares could be worth.

The stock’s next move may depend on whether the current share price can be squared with what Jazz Pharmaceuticals is earning right now and is reasonably expected to earn over time.

If you want a broader watchlist of companies where earnings and price are central to the story, a focused screen of 40 high quality undervalued stocks can be a useful second starting point for research.

Does Jazz Pharmaceuticals Look Pricey on Earnings?

The P/E ratio fits Jazz Pharmaceuticals because earnings remain the key yardstick investors use to weigh drug developers with established product portfolios. The current P/E sits around 71.8x, which is more than double the peer average near 31.2x and well above the broader pharmaceuticals sector on roughly 15.2x. That kind of gap indicates the market is putting a rich tag on each dollar of Jazz Pharmaceuticals earnings compared with many drugmakers.

Despite the setback around the Zepzelca phase 3 LAGOON trial update, the share price still trades at a premium to the fair multiple implied by its own fundamentals, so the model classifies the stock as overvalued on earnings. The Fair Ratio adjusts for Jazz Pharmaceuticals growth outlook, profitability profile and risk mix, and the current P/E sits above that hurdle. This suggests investors are paying a higher price for the story today rather than getting it at a discount. Explore the numbers behind Jazz Pharmaceuticals’s P/E valuation.

NasdaqGS:JAZZ P/E Ratio as at Nov 2026

NasdaqGS:JAZZ P/E Ratio as at Nov 2026

The Jazz Pharmaceuticals Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives for Jazz Pharmaceuticals pick up where the valuation puzzle leaves off and explain what assumptions about future growth, profitability and earnings would need to hold for the shares to be worth significantly more or less than today. Each storyline links a fair value estimate to a specific mix of potential catalysts and risks around Jazz Pharmaceuticals’ pipeline and cash flows, so you can track over time which version of events is actually unfolding on the Community page.

Leave a comment